The latest Medicare guidance will stifle pharmaceutical innovation—and it’s worse than we thought.
By Tomas J. Philipson
“The Biden administration has issued guidance on how it will implement the Medicare drug price controls in the Inflation Reduction Act. The controls will be far-reaching and much worse for the health of the country than critics had anticipated.”
Read the full article here.